These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 29954814)

  • 1. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia.
    Stein AS; Larson RA; Schuh AC; Stevenson W; Lech-Maranda E; Tran Q; Zimmerman Z; Kormany W; Topp MS
    Blood Adv; 2018 Jul; 2(13):1522-1531. PubMed ID: 29954814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
    Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
    J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
    Kantarjian H; Stein A; Gökbuget N; Fielding AK; Schuh AC; Ribera JM; Wei A; Dombret H; Foà R; Bassan R; Arslan Ö; Sanz MA; Bergeron J; Demirkan F; Lech-Maranda E; Rambaldi A; Thomas X; Horst HA; Brüggemann M; Klapper W; Wood BL; Fleishman A; Nagorsen D; Holland C; Zimmerman Z; Topp MS
    N Engl J Med; 2017 Mar; 376(9):836-847. PubMed ID: 28249141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia.
    Dombret H; Topp MS; Schuh AC; Wei AH; Durrant S; Bacon CL; Tran Q; Zimmerman Z; Kantarjian H
    Leuk Lymphoma; 2019 Sep; 60(9):2214-2222. PubMed ID: 30947585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.
    Topp MS; Stein AS; Gökbuget N; Horst HA; Boissel N; Martinelli G; Kantarjian H; Brüggemann M; Chen Y; Zugmaier G
    Cancer Med; 2021 Apr; 10(8):2601-2610. PubMed ID: 33734596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.
    Kantarjian HM; Stein AS; Bargou RC; Grande Garcia C; Larson RA; Stelljes M; Gökbuget N; Zugmaier G; Benjamin JE; Zhang A; Jia C; Topp MS
    Cancer; 2016 Jul; 122(14):2178-85. PubMed ID: 27143254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
    Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.
    Delea TE; Zhang X; Amdahl J; Boyko D; Dirnberger F; Campioni M; Cong Z
    Pharmacoeconomics; 2019 Sep; 37(9):1177-1193. PubMed ID: 31218655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
    Stein A; Franklin JL; Chia VM; Arrindell D; Kormany W; Wright J; Parson M; Amouzadeh HR; Choudhry J; Joseph G
    Drug Saf; 2019 May; 42(5):587-601. PubMed ID: 30565020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy.
    Kuchimanchi M; Zhu M; Clements JD; Doshi S
    Br J Clin Pharmacol; 2019 Apr; 85(4):807-817. PubMed ID: 30645768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
    JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Kobayashi Y; Oh I; Miyamoto T; Lee WS; Iida H; Minami H; Maeda Y; Jang JH; Yoon SS; Yeh SP; Tran Q; Morris J; Franklin J; Kiyoi H
    Asia Pac J Clin Oncol; 2022 Jun; 18(3):311-318. PubMed ID: 34185953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Dombret H; Bonifacio M; Reichle A; Graux C; Faul C; Diedrich H; Topp MS; Brüggemann M; Horst HA; Havelange V; Stieglmaier J; Wessels H; Haddad V; Benjamin JE; Zugmaier G; Nagorsen D; Bargou RC
    Blood; 2018 Apr; 131(14):1522-1531. PubMed ID: 29358182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Horibe K; Morris JD; Tuglus CA; Dos Santos C; Kalabus J; Anderson A; Goto H; Ogawa C
    Int J Hematol; 2020 Aug; 112(2):223-233. PubMed ID: 32564243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors.
    Stein AS; Schiller G; Benjamin R; Jia C; Zhang A; Zhu M; Zimmerman Z; Topp MS
    Ann Hematol; 2019 Jan; 98(1):159-167. PubMed ID: 30238148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
    Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
    Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.